How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?

In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of the vaccinia virus vaccine on the immune response against the monkeypox virus.

Study: Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. Image Credit: LookerStudio/Shutterstock
Study: Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. Image Credit: LookerStudio/Shutterstock

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Background

Since May 2022, an emerging cluster of monkeypox infections has been reported in humans and detected in non-endemic countries. Vaccinia virus vaccines have demonstrated high effectiveness against monkeypox viruses and are deemed an essential control measure. 

About the study

In the present study, researchers reported the effect of the vaccinia virus (VACV) on the human immune response against the monkeypox viruses (MPXV).

The team obtained 75 complete genomic sequences of MPXV-2022 from the Global Initiative on Sharing All Influenza Data (GISAID) database on 7 June 2022. The complete genomic sequences and references for the MPXV and the VACV were obtained from the National Center for Biotechnology Information (NCBI). The team developed an in-house bioinformatics pipeline to align these nucleotide sequences and their translation into amino acid residues. The amino acid translation was achieved based on the coding sequence positions as per the reference sequences corresponding to the VACV, as well as the location of the gene.

The team used multiple alignments using fast Fourier transform (MAFFT) software to assess all multiple sequence alignments. Coding sequences corresponding to 182 genes were described as per the sequence of the VACV reference, and the translated genomic regions present in the MPXV sequences represented the 182 MPXV-2022 ortholog proteins. The team also computed genetic similarities between any pair of protein sequences or nucleotides from pairwise sequence alignments. Furthermore, eight VACVC proteins that elicit neutralizing antibodies (NAbs) were evaluated among the MPXV-congo basin (MPXV-CB) reference and the MPXV-2022 sequences.         

Results

The study results showed that the MPXV-2022 sequences displayed an 84% mean genetic similarity with the reference VACV sequence. Also, approximately 3% of single nucleotide proteins (SNPs) and 13% of indels were detected, which translated to almost 6,500 SNPs and 27,500 indels. The eight immunogenic proteins present in the VACV exhibited genetic similarity ranging between 94% and 98% between the VAXV sequences and the MPXV-CB and MPXV-2022 sequences.

The specific mutations between the eight immunogenic proteins present in the VACV and both the MPXV-CB reference and the MPXV-2022 consensus sequences showed the same mutation groups for four out of the eight proteins. The rest of the proteins also revealed similarities between most of the mutations. Furthermore, the team noted that the MPXV-CB reference and the MPXV-2022 consensus sequences displayed one or two additional sets of mutations. Moreover, common mutations with respect to the VACV were mostly found in the D8L and H3L proteins. Mapping these mutations showed that for H3L, seven out of 19 mutations were exposed and were hence susceptible to targeting antibodies.

The team also noted a high degree of similarity between the VACV proteins that reported a minimum of one T cell epitope and orthologs corresponding to the MPXV-CB and MPXV-2022. This indicated substantial levels of cross-reactivity of T-cell responses stimulated by VACV against MPXV-2022. Among the 121 proteins comprising at least one T cell epitope, 388 were T cell epitopes derived from VACV. Furthermore, the team detected that 71.6% of the epitopes were similar between the MPXV-CB and MPXV-2022 sequences. The rest of the epitopes displayed only 1.55%, 1.8%, and 25% of the variation in only MPXV-2022, MPXV-CB, and both MPXV-CB and MPXV-2022, respectively. Overall, this revealed that while there was a high degree of similarity between the VACV proteins and the MPXV-CB and MPXV-2022 orthologs, genetic variation was significant in more than one-fourth of the T-cell epitopes.

Furthermore, the team observed that 25% of the T-cell epitopes present in the VACV sequences varied in MPXV-CB as well as MPXV-2022. However, 70% of these different T-cell epitopes had epitope mutations that were identical among both MPXV-CB and MPXV-2022. Altogether, this revealed that 89.2% of the T-cell epitope sequences were comparable in MPXV-CB and MPXV-2022.     

Conclusion

Overall, the study findings showed that MPXV displayed high genetic conservation within the immunogenic protein regions as well as epitopes corresponding to the VACV vaccination. The researchers believe that various studies reported the high efficacy of VACV vaccines needs further clinical evaluation.     

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2022, July 12). How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?. News-Medical. Retrieved on November 14, 2024 from https://www.news-medical.net/news/20220712/How-may-the-genetic-differences-observed-in-the-current-monkeypox-virus-outbreak-impact-immune-responses-induced-by-VACV-vaccines.aspx.

  • MLA

    Kunkalikar, Bhavana. "How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?". News-Medical. 14 November 2024. <https://www.news-medical.net/news/20220712/How-may-the-genetic-differences-observed-in-the-current-monkeypox-virus-outbreak-impact-immune-responses-induced-by-VACV-vaccines.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?". News-Medical. https://www.news-medical.net/news/20220712/How-may-the-genetic-differences-observed-in-the-current-monkeypox-virus-outbreak-impact-immune-responses-induced-by-VACV-vaccines.aspx. (accessed November 14, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2022. How may the genetic differences observed in the current monkeypox virus outbreak impact immune responses induced by VACV vaccines?. News-Medical, viewed 14 November 2024, https://www.news-medical.net/news/20220712/How-may-the-genetic-differences-observed-in-the-current-monkeypox-virus-outbreak-impact-immune-responses-induced-by-VACV-vaccines.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer extends agreement with genetic medicines customer